Caligiuri M, Weiden P, Legedza A, Yagoda S, Claxton A
Schizophr Bull Open. 2024; 3(1):sgac018.
PMID: 39144789
PMC: 11205961.
DOI: 10.1093/schizbullopen/sgac018.
Oliver D, Chesney E, Cullen A, Davies C, Englund A, Gifford G
Neurosci Biobehav Rev. 2024; 162:105699.
PMID: 38710421
PMC: 11250118.
DOI: 10.1016/j.neubiorev.2024.105699.
McCutcheon R, Taylor D, Rubio J, Nour J, Pillinger T, Murray R
Schizophr Bull. 2023; 50(3):513-520.
PMID: 37797288
PMC: 11059789.
DOI: 10.1093/schbul/sbad139.
Grosu S, Dobre M, Milanesi E, Hinescu M
Biomedicines. 2023; 11(9).
PMID: 37760977
PMC: 10525934.
DOI: 10.3390/biomedicines11092536.
Grace A, Uliana D
Int J Mol Sci. 2023; 24(15).
PMID: 37569748
PMC: 10418544.
DOI: 10.3390/ijms241512374.
Experimental Medicine Approaches in Early-Phase CNS Drug Development.
English B, Ereshefsky L
Adv Neurobiol. 2023; 30:417-455.
PMID: 36928860
DOI: 10.1007/978-3-031-21054-9_17.
The Relationship Between Cannabis, Cognition, and Schizophrenia: It's Complicated.
Kayir H, Ruffolo J, McCunn P, Khokhar J
Curr Top Behav Neurosci. 2022; 63:437-461.
PMID: 36318403
DOI: 10.1007/7854_2022_396.
Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives.
Weston-Green K
Front Psychiatry. 2022; 13:903156.
PMID: 35782443
PMC: 9243257.
DOI: 10.3389/fpsyt.2022.903156.
Application of positron emission tomography in psychiatry-methodological developments and future directions.
Cervenka S, Frick A, Boden R, Lubberink M
Transl Psychiatry. 2022; 12(1):248.
PMID: 35701411
PMC: 9198063.
DOI: 10.1038/s41398-022-01990-2.
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone.
Perlstein I, Merenlender Wagner A, Gomeni R, Lamson M, Harary E, Spiegelstein O
Clin Pharmacol Drug Dev. 2022; 11(7):865-877.
PMID: 35245409
PMC: 9315033.
DOI: 10.1002/cpdd.1078.
Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.
Maini K, Hollier J, Gould H, Bollich V, John LaForge J, Cornett E
Health Psychol Res. 2021; 9(1):24932.
PMID: 34746489
PMC: 8567771.
DOI: 10.52965/001c.24932.
Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia.
Kim J, Pae C, Han C, Bahk W, Lee S, Patkar A
Clin Psychopharmacol Neurosci. 2021; 19(4):600-609.
PMID: 34690115
PMC: 8553537.
DOI: 10.9758/cpn.2021.19.4.600.
Synthesis and In Vitro Evaluation of Novel Dopamine Receptor D 3,4-dihydroquinolin-2(1)-one Derivatives Related to Aripiprazole.
Juza R, Stefkova K, Dehaen W, Randakova A, Petrasek T, Vojtechova I
Biomolecules. 2021; 11(9).
PMID: 34572475
PMC: 8464836.
DOI: 10.3390/biom11091262.
No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis.
Lee M, Fatouros-Bergman H, Plaven-Sigray P, Ikonen Victorsson P, Sellgren C, Erhardt S
NPJ Schizophr. 2021; 7(1):46.
PMID: 34548499
PMC: 8455597.
DOI: 10.1038/s41537-021-00176-x.
History of the dopamine hypothesis of antipsychotic action.
Seeman M
World J Psychiatry. 2021; 11(7):355-364.
PMID: 34327128
PMC: 8311512.
DOI: 10.5498/wjp.v11.i7.355.
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets.
luptak M, Michalickova D, Fisar Z, Kitzlerova E, Hroudova J
World J Psychiatry. 2021; 11(7):277-296.
PMID: 34327122
PMC: 8311514.
DOI: 10.5498/wjp.v11.i7.277.
The Pharmacodynamics of Antipsychotic Drugs in Women and Men.
Seeman M
Front Psychiatry. 2021; 12:650904.
PMID: 33897500
PMC: 8062799.
DOI: 10.3389/fpsyt.2021.650904.
PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain.
Smart K, Naganawa M, Baldassarri S, Nabulsi N, Ropchan J, Najafzadeh S
Cereb Cortex. 2021; 31(6):2787-2798.
PMID: 33442731
PMC: 8355478.
DOI: 10.1093/cercor/bhaa387.
Neuroimaging Biomarkers in Schizophrenia.
Kraguljac N, McDonald W, Widge A, Rodriguez C, Tohen M, Nemeroff C
Am J Psychiatry. 2021; 178(6):509-521.
PMID: 33397140
PMC: 8222104.
DOI: 10.1176/appi.ajp.2020.20030340.
An open-label, positron emission tomography study of the striatal D/D receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants.
Wong D, Raoufinia A, Bricmont P, Brasic J, McQuade R, Forbes R
Eur J Clin Pharmacol. 2020; 77(5):717-725.
PMID: 33196868
PMC: 8032567.
DOI: 10.1007/s00228-020-03021-9.